Clinical trials
Active, not recruiting Diabetes Mellitus trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
106 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 11 |
| 2023 | 16 |
| 2024 | 22 |
| 2025 | 18 |
| 2026 | 13 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 106 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Johns Hopkins University | 3 |
| National Taiwan University Hospital | 3 |
| University of Pennsylvania | 3 |
| Cairo University | 2 |
| Kaiser Permanente | 2 |
| University of California, San Francisco | 2 |
| University of North Carolina, Chapel Hill | 2 |
| University of Pittsburgh | 2 |
| Aalborg University Hospital | 1 |
| Albert Einstein College of Medicine | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus | 106 |
| Hypertension | 26 |
| Diabetes Mellitus, Type 2 | 20 |
| Obesity | 20 |
| Diabetes Mellitus, Type 1 | 11 |
| Cardiovascular Diseases | 9 |
| Overweight | 8 |
| Prediabetic State | 7 |
| Neoplasms | 6 |
| Insulin Resistance | 5 |
Trials
Showing 1 to 25 of 106. Each trial links to its page on Pharma Observatory.
6 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.